LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of November 6, 2026, LXRX stock price climbed to $1.78 with 1,633,405 million shares trading.

LXRX has a beta of 0.68, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.01 to the broad based SPY ETF.

LXRX has a market cap of $792.02 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $11 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.02.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWO.

LXRX has outperformed the market in the last year with a price return of +29.0% while the SPY ETF gained +9.9%. However, in the short term, LXRX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -27.3% vs -4.0% return in SPY. But in the last 2 weeks, LXRX shares have fared better than the market returning +19.5% compared to SPY -3.5%.

LXRX support price is $1.55 and resistance is $1.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.